2022
Antagonism of miR-148a attenuates atherosclerosis progression in APOB TG Apobec -/- Ldlr +/- mice: A brief report
Rotllan N, Zhang X, Canfrán-Duque A, Goedeke L, Griñán R, Ramírez CM, Suárez Y, Fernández-Hernando C. Antagonism of miR-148a attenuates atherosclerosis progression in APOB TG Apobec -/- Ldlr +/- mice: A brief report. Biomedicine & Pharmacotherapy 2022, 153: 113419. PMID: 36076541, PMCID: PMC11140622, DOI: 10.1016/j.biopha.2022.113419.Peer-Reviewed Original ResearchConceptsProgression of atherosclerosisMiR-148aLipoprotein cholesterolAtherosclerotic lesionsHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolAnti-inflammatory effectsAnti-inflammatory genesMacrophage cholesterol effluxWestern-style dietMiR-148a levelsHepatic gene expressionMurine primary macrophagesAntiatherogenic effectsAtherosclerosis progressionInflammatory responseTherapeutic silencingLipoprotein metabolismPlaque stabilityCholesterol effluxPrimary macrophagesPlaque sizeCholesterol homeostasisLesionsMRNA levels
2021
Deficiency of histone lysine methyltransferase SETDB2 in hematopoietic cells promotes vascular inflammation and accelerates atherosclerosis
Zhang X, Sun J, Canfrán-Duque A, Aryal B, Tellides G, Chang YJ, Suárez Y, Osborne TF, Fernández-Hernando C. Deficiency of histone lysine methyltransferase SETDB2 in hematopoietic cells promotes vascular inflammation and accelerates atherosclerosis. JCI Insight 2021, 6: e147984. PMID: 34003795, PMCID: PMC8262461, DOI: 10.1172/jci.insight.147984.Peer-Reviewed Original ResearchConceptsHematopoietic cellsHistone methylation/acetylationSingle-cell RNA-seq analysisMethylation/acetylationHistone H3 Lys9RNA-seq analysisProgression of atherosclerosisEpigenetic marksLysine methyltransferasesH3 Lys9Epigenetic modificationsDNA methylationNoncoding RNAsCell regulatorsSETDB2Vascular inflammationAtherosclerotic lesionsAtherosclerotic plaquesMyeloid cell recruitmentGenetic deletionLDLR knockout miceEnhanced expressionHepatic lipid metabolismMurine atherosclerotic lesionsGenes
2016
Chronic miR‐29 antagonism promotes favorable plaque remodeling in atherosclerotic mice
Ulrich V, Rotllan N, Araldi E, Luciano A, Skroblin P, Abonnenc M, Perrotta P, Yin X, Bauer A, Leslie KL, Zhang P, Aryal B, Montgomery RL, Thum T, Martin K, Suarez Y, Mayr M, Fernandez-Hernando C, Sessa WC. Chronic miR‐29 antagonism promotes favorable plaque remodeling in atherosclerotic mice. EMBO Molecular Medicine 2016, 8: 643-653. PMID: 27137489, PMCID: PMC4888854, DOI: 10.15252/emmm.201506031.Peer-Reviewed Original ResearchConceptsPlaque morphologyReduced lesion sizeAcute myocardial infarctionAtherosclerotic mouse modelVulnerable atherosclerotic lesionsFibrous cap thicknessPlaque extracellular matrixChronic administrationExtracellular matrixAtherosclerotic miceMyocardial infarctionPlaque remodelingSolid organsAbnormal remodelingMouse modelAtherosclerotic lesionsAtherosclerotic plaquesBlood chemistryLesion sizeMiR-29Necrotic zoneLesionsPlaquesCap thicknessMiR-29 target genes
2000
Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells
Montero M, Hernández O, Suárez Y, Matilla J, Ferruelo A, Martı́nez-Botas J, Gómez-Coronado D, Lasunción M. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis 2000, 153: 303-313. PMID: 11164419, DOI: 10.1016/s0021-9150(00)00417-2.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsMononuclear cellsHuman peripheral blood mononuclear cellsTh1 cytokine releaseTh2 cytokine releaseTh1/Th2Blood mononuclear cellsEffect of fluvastatinCaspase-1 activationCaspase-1 activityLate atherosclerotic lesionsTh1 responseIL-10Fluvastatin treatmentIL-12IL-18Exerts actionsCytokine releaseIL-4Cholesterol levelsT cellsAtherosclerotic lesionsImmune functionStatinsCaspase-1